SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates.
SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates.
复制标题
DOI：
10.1016/s0140-6736(20)32137-1
复制
发表时间：
2020-11-14
期刊：
影响因子：
--
通讯作者：
Kennedy RB
中科院分区：
文献类型：
--
作者：
Poland GA;Ovsyannikova IG;Kennedy RB
了解对严重急性呼吸综合征冠状病毒2的免疫反应对于了解疾病的发病机制和桥梁疗法（如超免疫球蛋白和恢复期人血浆）的有效性以及开发疫苗，抗病毒药和单克隆抗体至关重要。仅仅11个月前，我们称之为COVID-19的画布还是一片空白。世界各地的科学家们通力合作，填补了这一空白。在这篇综述中，我们讨论了目前已知的人类对严重急性呼吸综合征冠状病毒2的体液和细胞免疫反应，并将这些知识与目前处于3期临床试验的COVID-19疫苗联系起来。
Understanding immune responses to severe acute respiratory syndrome coronavirus 2 is crucial to understanding disease pathogenesis and the usefulness of bridge therapies, such as hyperimmune globulin and convalescent human plasma, and to developing vaccines, antivirals, and monoclonal antibodies. A mere 11 months ago, the canvas we call COVID-19 was blank. Scientists around the world have worked collaboratively to fill in this blank canvas. In this Review, we discuss what is currently known about human humoral and cellular immune responses to severe acute respiratory syndrome coronavirus 2 and relate this knowledge to the COVID-19 vaccines currently in phase 3 clinical trials.